Artelo Biosciences Reveals Preliminary Findings from Food Effect Study on ART26.12, an Innovative Non-Opioid Candidate for Chronic Pain Management
Positive Clinical Trial Results: Artelo Biosciences announced successful results from a Phase 1 clinical trial of ART26.12, a fatty acid binding protein 5 (FABP5) inhibitor, showing a favorable safety profile and predictable pharmacokinetics in both fed and fasted conditions.
Safety Profile Findings: The study involved healthy volunteers receiving three doses of ART26.12, with no serious adverse events reported, indicating that the drug is well-tolerated.
Advancement to Further Trials: The encouraging data from the single ascending dose and food effect studies support moving forward to a multiple ascending dose trial planned for the fourth quarter of this year.
Therapeutic Potential: ART26.12 represents a new non-opioid approach to pain management, targeting mechanisms relevant to chronic pain conditions, including chemotherapy-induced peripheral neuropathy.
Trade with 70% Backtested Accuracy
Analyst Views on ARTL
About ARTL
About the author
Maxim Group Lowers Artelo Biosciences Rating to Hold
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
Wolfspeed Shares Surge Over 50%; Check Out 20 Stocks Making Moves in Premarket Trading
Wolfspeed's Reorganization: Wolfspeed, Inc. announced a court-approved reorganization plan that will reduce its debt by 70% and interest payments by 60%, leading to a 50.9% increase in its stock price during pre-market trading.
Other Notable Stock Movements: Several companies saw significant pre-market trading gains, including Sunrise New Energy Co. (up 97%) and Vivakor, Inc. (up 67%), while others like Epsium Enterprise Limited and Artelo Biosciences, Inc. experienced notable declines.
Artelo Biosciences Initiates Underwritten Public Offering to Secure Funding
Public Offering Announcement: Artelo Biosciences has initiated an underwritten public offering of its common stock and/or pre-funded warrants, with all shares being offered by the company.
Market Conditions Impact: The completion, final size, and terms of the offering are contingent on market conditions, and there is no assurance regarding the timing or completion of the offering.
Artelo Biosciences Unveils Plans for Underwritten Public Offering
Public Offering Announcement: Artelo Biosciences, Inc. has initiated an underwritten public offering of its common stock and/or pre-funded warrants, with the offering subject to market conditions and no assurance of completion or specific terms.
Company Overview: Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments for various conditions, including cancer and pain, by modulating lipid-signaling pathways, and is led by an experienced executive team.
Science Applications International Analyst Changes Outlook; Top 3 Downgrades for Monday Revealed
Analyst Downgrades: JP Morgan downgraded Science Applications International Corporation (SAIC) from Overweight to Neutral, lowering the price target from $140 to $115, with shares closing at $104.93.
Artelo Biosciences Rating Change: D. Boral Capital downgraded Artelo Biosciences, Inc. from Buy to Hold, with shares closing at $4.51.
ABM Industries Adjustment: Baird analyst downgraded ABM Industries Incorporated from Outperform to Neutral, reducing the price target from $56 to $54, while shares closed at $48.26.
Market Overview: The article provides insights into various stock performances and analyst ratings, highlighting significant changes in outlook for several companies.
Artelo Biosciences Completes $3 Million Public Offering of Common Stock and Pre-Funded Warrants
Public Offering Details: Artelo Biosciences, Inc. closed an underwritten public offering of 640,924 shares of common stock at $4.40 per share, along with pre-funded warrants for 40,894 shares at $4.399 each, raising approximately $3 million in gross proceeds.
Market Performance: Following the offering, Artelo's stock closed at $4.51, reflecting a 3.68% increase, with no after-hours trading activity reported on NasdaqCM.
Maxim Group Lowers Artelo Biosciences Rating to Hold
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
Wolfspeed Shares Surge Over 50%; Check Out 20 Stocks Making Moves in Premarket Trading
Wolfspeed's Reorganization: Wolfspeed, Inc. announced a court-approved reorganization plan that will reduce its debt by 70% and interest payments by 60%, leading to a 50.9% increase in its stock price during pre-market trading.
Other Notable Stock Movements: Several companies saw significant pre-market trading gains, including Sunrise New Energy Co. (up 97%) and Vivakor, Inc. (up 67%), while others like Epsium Enterprise Limited and Artelo Biosciences, Inc. experienced notable declines.
Artelo Biosciences Initiates Underwritten Public Offering to Secure Funding
Public Offering Announcement: Artelo Biosciences has initiated an underwritten public offering of its common stock and/or pre-funded warrants, with all shares being offered by the company.
Market Conditions Impact: The completion, final size, and terms of the offering are contingent on market conditions, and there is no assurance regarding the timing or completion of the offering.
Artelo Biosciences Unveils Plans for Underwritten Public Offering
Public Offering Announcement: Artelo Biosciences, Inc. has initiated an underwritten public offering of its common stock and/or pre-funded warrants, with the offering subject to market conditions and no assurance of completion or specific terms.
Company Overview: Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments for various conditions, including cancer and pain, by modulating lipid-signaling pathways, and is led by an experienced executive team.
Science Applications International Analyst Changes Outlook; Top 3 Downgrades for Monday Revealed
Analyst Downgrades: JP Morgan downgraded Science Applications International Corporation (SAIC) from Overweight to Neutral, lowering the price target from $140 to $115, with shares closing at $104.93.
Artelo Biosciences Rating Change: D. Boral Capital downgraded Artelo Biosciences, Inc. from Buy to Hold, with shares closing at $4.51.
ABM Industries Adjustment: Baird analyst downgraded ABM Industries Incorporated from Outperform to Neutral, reducing the price target from $56 to $54, while shares closed at $48.26.
Market Overview: The article provides insights into various stock performances and analyst ratings, highlighting significant changes in outlook for several companies.
Artelo Biosciences Completes $3 Million Public Offering of Common Stock and Pre-Funded Warrants
Public Offering Details: Artelo Biosciences, Inc. closed an underwritten public offering of 640,924 shares of common stock at $4.40 per share, along with pre-funded warrants for 40,894 shares at $4.399 each, raising approximately $3 million in gross proceeds.
Market Performance: Following the offering, Artelo's stock closed at $4.51, reflecting a 3.68% increase, with no after-hours trading activity reported on NasdaqCM.
